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Abstract
The ability of CCL2 to influence prostate cancer tumori-
genesis and metastasis may occur through two distinct
mechanisms: 1) a direct effect on tumor cell growth
and function, and 2) an indirect effect on the tumor
microenvironment by the regulation of macrophagemo-
bilization and infiltration into the tumor bed. We have
previously demonstrated that CCL2 exerts a direct ef-
fect on prostate cancer epithelial cells by the regula-
tion of their growth, invasion, and migration, resulting
in enhanced tumorigenesis and metastasis. Here we
describe an indirect effect of CCL2 on prostate cancer
growth and metastasis by regulating monocyte/macro-
phage infiltration into the tumor microenvironment and
by stimulating a phenotypic change within these im-
mune cells to promote tumor growth (tumor-associated
macrophages). VCaP prostate cancer cells were sub-
cutaneously injected in male SCID mice and monitored
for tumor volume, CD68+ macrophage infiltration, and
microvascular density. Systemic administration of anti-
CCL2 neutralizing antibodies (CNTO888 and C1142) sig-
nificantly retarded tumor growth and attenuated CD68+
macrophage infiltration, which was accompanied by a
significant decrease in microvascular density. These
data suggest that CCL2 contributes to prostate cancer
growth through the regulation of macrophage infiltra-
tion and enhanced angiogenesis within the tumor.
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Introduction
The mechanisms by which elevated levels of chemokines
and upregulation of chemokine receptors influence cancer
development and metastasis remain unclear. Increasing
evidence suggests that chemokines secreted from stromal
elements (e.g., bone marrow endothelial cells) directly
stimulate tumor cells that express (or overexpress) chemo-
kine receptors and regulate tumor cell proliferation and
migration [1]. Alternatively, tumor cells can secrete ele-
vated levels of chemokines to induce a paracrine/autocrine
response on tumor growth. Dysregulation of chemokines and
chemokine receptors has been demonstrated to alter tumor
development and progression through enhanced proliferation,
increased invasiveness, increased angiogenesis, and recruit-
ment of immune cells that promote tumor growth (e.g., tumor-
associated macrophages or TAMs). Monocyte chemoattractant
protein 1 (CCL2) is a member of the cytokine/chemokine
superfamily and is known to promote the migration of mono-
cytes and macrophages to sites of inflammation. Recently,
CCL2 has been shown to be an active mediator of the tumori-
genesis and metastasis of several solid tumors, including a role
in regulating the migration and proliferation of breast cancer,
multiple myeloma, and, recently, prostate cancer [2–6].
Lu et al. [7] examined CCL2 expression in 83 patients
with prostate cancer and determined that CCL2 expression
correlated with advanced stage and that prostate cancer
cells produced CCL2 in vitro, which mediated proliferation
and invasion in an autocrine/paracrine manner. We have pre-
viously reported the ability of CCL2 to influence prostate can-
cer tumorigenesis and metastasis through a direct promotional
effect on tumor cell proliferation and migration [6]. We have
also demonstrated that prostate cancer cells in vitro and in
human cancer tissues exhibit an upregulation of the CCL2
receptor CCR2. Here we describe an indirect effect of CCL2
on prostate cancer growth and metastasis through the regu-
lation of macrophage infiltration and enhanced angiogene-
sis within the tumor. Using anti–human (CNTO888)–specific
and anti–mouse (C1142)–specific neutralizing antibodies to
CCL2, we demonstrate inhibition of prostate tumor growth
and migration in vivo through direct effects on prostate can-
cer cells and blocking of TAM infiltration into the tumors (indi-
rect effects).
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Materials and Methods
Materials
Human recombinant CCL2 was obtained from Chemicon
International (Temecula, CA); anti–phospho AktSer473, anti-
Akt, anti–phospho p44/p42, and anti– total p44/p42 were
obtained from Cell Signaling (Beverly, MA); and all other
reagents were obtained from Sigma-Aldrich (St. Louis, MO).
Description of CNTO888 and C1142, and Control Antibodies
CNTO888 is a human IgG1n antibody that neutralizes
human CCL2 (Centocor, Inc., Malvern, PA). C1142 is a rat/
mouse chimeric antibody that neutralizes mouse CCL2/JE.
CNTO888 and C1142 do not cross-react with or neutralize
mouse CCL2/JE or human CCL2, respectively (data not
shown). Clinical-grade human IgG (huIgG) served as a
negative control for CNTO888, whereas C1322 rat/mouse
chimeric nonspecific antibody (Centocor, Inc.) served as a
negative control for C1142.
Cell Culture
VCaP cells are a human prostate cancer cell line derived
from vertebral bone metastasis [8]. VCaP cells were main-
tained in Dulbecco’s modified Eagle’s medium 1640 + 10%
fetal calf serum (Invitrogen, Carlsbad, CA). Cells were pas-
saged by trypsinization using 1 trypsin + EDTA (Invitrogen)
and resuspended in appropriate growth media.
Xenograft Model of Tumorigenesis
Xenograft tumors were established as previously de-
scribed [9]. Briefly, male SCID mice (5–6 weeks of age)
were injected subcutaneously in the flank with 1  106 VCaP
cells in 200 ml of Matrigel (BD Biosciences, Inc., San Jose,
CA). Tumor volumes were calculated by caliper measure-
ments performed weekly to monitor and track tumor growth
(tumor volume = LWW  0.56). Mice were separated into
one of four groups (n = 5 per group): 1) huIgG; 2) C1322
control mouse antibody; 3) anti-CCL2 (CNTO888); and 4)
anti-CCL2/JE (C1142). Mice were treated with 2 mg/kg anti-
body, twice weekly, by intraperitoneal injection beginning on
day 28 and for the remainder of the study.
Histology
Xenograft tumors were harvested and placed in fresh 10%
formalin. Tumors were paraffin-embedded, and 5-mm sec-
tions were cut and placed on glass slides. Hematoxylin–eosin
staining was performed according to the manufacturer’s in-
structions (Sigma, Inc.,St. Louis,MO). Identificationof neovas-
cularization was accomplished by labeling with an anti-CD31
antibody, and macrophage infiltration was identified using
an anti-CD68 antibody. Tissue sections were incubated for
10minutes in citrate buffer (pH 6.0) andmicrowaved. Sections
were incubated with anti-CD31 (1:50; DakoCytomation, Inc.,
Carpinteria, CA) or anti-CD68 (1:1600; DakoCytomation, Inc.)
for 30 minutes and detected with LSAB + detection/DAB (3,3V-
diaminobenzidine; Sigma, Inc.) for 5 minutes. Slides were
dipped in hematoxylin for 1 second as a counterstain.
Endothelial Tube Formation Assay
In vitro tube formation was performed as previously de-
scribed [10]. Growth factor–reduced Matrigel was diluted
with cold serum-free medium to a concentration of 10 mg/ml.
Fifty microliters of the solution was added to each well
of a 96-well plate and allowed to form a gel at 37jC for
30 minutes. Human dermal microvacular endothelial cells
(HDMVECs; 150,000 cells/ml) in VCaP conditioned media
(VCaP CM) were added to each well and incubated over-
night at 37jC in 5% CO2. Either control antibodies (huIgG
or C1322; 30 mg/ml) or anti-CCL2 antibodies (CNTO888
and/or C1142; 30 mg/ml) were added to the conditioned
media. Under these conditions, endothelial cells will form
delicate networks of tubes that are detectable within 2
to 3 hours and are fully developed after 8 to 12 hours.
After overnight incubation, the wells were washed, and the
Matrigel and its endothelial tubes were fixed with 3% para-
formaldehyde. Tube formation was quantified by counting
the number of sprouts that developed per objective field
(100), and assays were performed in triplicate from three
independent experiments.
Macrophage Migration
Human recombinant CCL2 was used as a chemoattractant
in the lower chamber of a modified Boyden chamber. Cells
were harvested by 0.5 mM EDTA release and resuspended
in serum-free media at 5  104 cells/ml. A total of 2.5 
104 cells was added to the upper chamber of the transwell
insert and incubated for 24 hours at 37jC and 5% CO2
atmosphere. At the end of the incubation period, the cells
were fixed with 4% formaldehyde in phosphate-buffered
saline for 5 minutes. Nonadherent cells were removed from
inserts with cotton-tipped swab. Cells that had migrated to
the underside of the inserts were stained with 0.5% crystal
violet for 5 minutes and rinsed thoroughly with tap water.
The inserts were allowed to dry, and the cells were counted
using an inverted microscope.
Immunoblot Analysis
Cells were lysed in RIPA buffer (50 mM Tris–HCl pH 7.4,
1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM
Na3VO4, 1 mMNaF, 1 mM okadaic acid, and 1 mg/ml aprotinin,
leupeptin, and pepstatin). Proteins were separated under re-
ducing conditions by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred onto nitrocellulose mem-
branes. The membranes were blocked with 5% milk in
0.1% Tween in Tris-buffered saline (TBS) for 1 hour at room
temperature and then were incubated overnight at 4jC with
primary antibodies. Membranes were washed thrice before
incubation with horseradish peroxidase–conjugated second-
ary antibodies (Cell Signaling) for 1 hour at room temperature.
Protein expression was visualized by ECL chemilumines-
cence (Promega, Madison, WI) and quantitated using Image
J software (NCI, Bethesda, MD).
Statistical Analysis
Data were analyzed with GraphPad Prism software
(GraphPad Software, Inc., San Diego, CA). One-way anal-
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ysis of variance was used with Bonferroni’s post hoc analy-
sis for comparison between multiple groups. Student’s t test
was used for comparison between two groups. Significance
was defined as P < .05.
Results
To determine the role of CCL2 in prostate cancer growth
in vivo, we implanted VCaP xenografts in male SCID mice
(n = 5) and monitored tumor growth by caliper measurement
and calculation of tumor volume. Twenty-eight days post-
implantation, tumors were approximately 200 mm3, and mice
were divided into therapy groups: 1) huIgG control antibody;
2) anti–human CCL2 antibody CNTO888; 3) mouse control
antibody C1322; and 4) anti–mouse CCL2/JE antibody
C1142. Mice were treated with antibodies at 2 mg/kg,
twice weekly, by intraperitoneal injection. Antibodies were
delivered for 3 weeks, and animals were sacrificed on
day 50. Tumor volume measurements revealed a 55% re-
duction in tumor growth on day 50 by the administration of
a neutralizing anti–mouse CCL2/JE antibody (C1142) com-
pared to the administration of C1322 (Figure 1A). Similarly,
Figure 1. Inhibition of tumor growth by neutralization of CCL2. Tumor volume was monitored weekly by caliper measurements in mice receiving C1142 versus
C1322 (A), and huIgG versus CNTO888 (B). Antibody treatment was initiated on day 28 (Tx) and administered at 2 mg/kg, i.p., twice weekly, for the duration of the
experiment. Immunohistochemical analysis of xenograft tumors displayed normal prostate adenocarcinoma morphology by hematoxylin–eosin staining in mice
treated with C1322 (C), C1142 (D), huIgG (G), or CNTO 888 (H). Neovascularization for each individual tumor (n = 5 per group; four fields per tumor) was
visualized by immunohistochemical staining of CD31, and representative sections are presented (E, F, I, and J). (K) The ability of CCL2 inhibition to reduce blood
vessel formation was analyzed using an in vitro tube formation assay. Tube formation using HDMVECs was induced by VCaP CM, and the number of sprouts per
100 objective field is displayed. The graph represents the mean of three independent experiments, each performed in triplicate (mean ± SD; *P < .01).
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administration of a neutralizing anti–human CCL2 antibody
(CNTO888) resulted in a 42% reduction in tumor volume
on day 50 compared to the administration of huIgG control
antibody (Figure 1B). These data suggest that inhibition
of either tumor-derived human CCL2 or stromal mouse–
derived CCL2/JE can significantly delay the growth of
these tumors.
To understand possible mechanisms by which antibodies
could delay tumor growth, xenograft tumors were collected
for histologic analysis and quantification of microvascular
density. Sections were stained for CD31 (PECAM, a marker
of vascular endothelium). Inhibition of CCL2 with either anti–
human CCL2 or anti–mouse CCL2/JE neutralizing antibodies
decreased the amount of angiogenesis as identified by a de-
crease inCD31 staining compared to isotype controls [Figure 1,
E and F (anti-mouse), and I and J (anti-human)]. To further
elucidate the role of CCL2 inhibition in blood vessel formation,
we applied an in vitro tube formation assay as previously
described [10]. Human dermal microvascular endothelial cells
grown in VCaP CM in Matrigel formed a capillary-like network
of tubes (Figure 1K ). Administration of either CNTO888 or
C1142 (30 mg/ml) to VCaP CM significantly reduced the
number of capillary-like tubes that formed compared to isotype
control antibody-treated cells (Figure 1K ).
Here we assessed the proliferative status of VCaP xeno-
grafts by immunohistochemical staining for Ki67 (a marker
of proliferation) and contrasted the effects on proliferation
with apoptosis by staining similar sections with an apoptosis
stain (ApopTag; Millipore, Billerica, MA) (Figure 2). Qualita-
tive analysis revealed that inhibition of host-derived CCL2
resulted in a significant decrease in Ki67 staining and a mod-
est induction of apoptosis (Figure 2, A–F ). Inhibition of
tumor-derived CCL2 did not demonstrate a significant induc-
tion of apoptosis (Figure 2, J and K ) and a mild decrease in
proliferation, as evidenced by a slight decrease in Ki67 stain-
ing (Figure 2, L and M ). The modest effect of anti-CCL2
therapy on apoptosis remains unclear; however, inhibition of
host-derived CCL2 significantly attenuated proliferation. This
decrease in Ki67 staining was accompanied by a decrease in
phosphorylated Akt and phosphorylated p44/p42 MAPK
Figure 2. Inhibition of mouse CCL2 reduces proliferation in VCaP xenografts. Apoptosis was visualized by immunohistochemical staining with ApopTag (A–D,
H–K). Proliferation was visualized by immunohistochemical staining for Ki67 (E–F, L–M).
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(Figure 3, A–H ). As a mechanism of induced proliferation,
VCaP cells were stimulated with increasing concentrations of
human CCL2 in vitro and demonstrated a dose-dependent
activation of Akt (Figure 4A) and p70 S6 kinase, a down-
stream target of Akt that is known to be important in cel-
lular proliferation (Figure 4B). Furthermore, we assessed
the inhibition of CCL2 using the anti–human CCL2 antibody
CNTO888 (30 mg/ml) to attenuate the in vitro proliferation of
VCaP cells. Administration of anti–human CCL2 antibodies
reduced the proliferation of VCaP cells over a 96-hour period
(Figure 4C ).
CCL2 is known to promote monocyte/macrophage infiltra-
tion into tissues, and the role of TAMs in prostate cancer
biology has demonstrated a direct role in the regulation of
tumor growth and angiogenesis [6,7]. We assessed macro-
phage infiltrates in xenograft tumors by immunohistochemistry.
Macrophages were identified by CD68+ (lysosomal glyco-
protein, a marker of monocytes and macrophages) staining.
Inhibition of CCL2 reduced monocyte/macrophage infiltra-
tion, as evidenced by a lack of CD68+ staining in treated
tumors compared to control tumors [Figure 5, A and C (anti-
human), and B and D (anti-mouse)]. Macrophage infiltra-
tion was quantified by manual counting of CD68+ cells per
100 objective field. Inhibition of either human or mouse
CCL2 demonstrated a significant decrease in the number of
CD68+ cells present within VCaP xenografts (huIgG: 85.33 ±
12.10; CNTO888: 9.00 ± 7.94; C1322: 131.00 ± 19.08; C1142:
13.67 ± 3.06; mean ± SD, P < .0001) (Figure 5E). Inhibition
of macrophage migration using CNTO888 was confirmed in
an in vitro migration assay (Figure 6). VCaP CM induced a
significant increase in the number of migrating human U937
premonocytic cells (a premacrophage cell line). Preincuba-
tion of U937 cells with CNTO888 (30 mg/ml) significantly
attenuated the migratory effect induced by VCaP CM (SFM:
33 ± 69; VCAP CM: 805 ± 28; huIgG: 756 ± 136; CNTO888:
225 ± 111; P < .001).
Discussion
We continue to gather increasing evidence demonstrating
an important role for CCL2 in prostate cancer tumorigenesis.
As a result of in vitro studies demonstrating that PCa cells
are stimulated to proliferate and migrate by CCL2, we sought
to determine the effects of CCL2 inhibition in vivo on tumor
growth and macrophage infiltration. The data presented here
describe the use of CCL2 neutralizing antibodies that spe-
cifically recognize either the human CCL2 (CNTO888) or the
mouse homolog CCL2/JE (C1142) in an in vivo xenograft
model of prostate cancer. Neutralizing antibodies that spe-
cifically inhibit human versus mouse CCL2 lend a powerful
tool for clearly dissecting the role of tumor-derived CCL2
(human CCL2) and host/microenvironment–derived CCL2
(mouse CCL2/JE). Tumor volume measurements revealed a
42% reduction of tumor growth on day 50 by the administra-
tion of a neutralizing anti–human CCL2 (CNTO888) anti-
body compared to human IgG control (Figure 1). Similarly,
the administration of a neutralizing anti–mouse CCL2/JE
(C1142) antibody resulted in a 55% reduction in tumor vol-
ume on day 50 compared to the administration of mouse
control antibody (Figure 1). These data suggest that CCL2
is produced directly by tumor cells and from stromal cells
of the microenvironment, both of which influence tumor
growth in vivo. These data do not indicate whether the
growth benefit of CCL2 is a reflection of direct tumor cell
stimulation by CCL2 or by CCL2-mediated changes in the
Figure 3. Inhibition of mouse CCL2 attenuates Akt and MAPK p44/p42 ac-
tivity. Tumor specimens were collected and stained with anti –phospho Akt
(A and B; E and F) or anti –phospho p44/p42 (C and D; G and H) to visualize
the intratumoral activity of these signaling pathways.
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microenvironment that impact tumor growth. Inhibition of
CCL2 with either anti–human CCL2 (CNTO888) or anti–
mouse CCL2/JE (C1142) neutralizing antibodies decreased
the amount of angiogenesis, as identified by a decrease in
CD31 staining compared to relevant control groups (Fig-
ure 1). Furthermore, inhibition of CCL2 attenuated mono-
cyte/macrophage infiltration as evidenced by a lack of CD68+
staining compared to controls (Figure 2). Although these
studies were performed in a small sample size (n = 5
per group) and differences were observed between the
two control antibody groups, these differences were not
significant, and a significant decrease in macrophage in-
filtration was quantified in both the anti–mouse CCL2/JE
(C1142) and the anti–human CCL2 (CNTO888) treatment
groups. These data suggest that inhibition of CCL2, both
tumor-derived and host-derived, attenuates the growth of
prostate cancer xenografts potentially by a dual mecha-
nism: 1) a direct effect on tumor cell survival and prolifera-
tion, and 2) changes in the microenvironment that provide
tumor cell advantage (e.g., angiogenesis and infiltration
of macrophages).
The pronounced decrease in tumor growth and the inhi-
bition of histologic Ki67 staining by anti–mouse CCL2 anti-
body C1142 suggest that the predominant mechanism of
CCL2-regulated tumor growth is the regulation of immune
cell infiltration (e.g., TAMs). TAMs are known to produce
elevated levels of mitogenic stimuli (e.g., VEGF) that di-
rectly stimulate prostate cancer cell growth and induce neo-
vascularization of neoplastic tissues. Interestingly, CCL2
has been demonstrated to play an important role in osteo-
clast activation in prostate cancer [11]. Osteoclasts are
terminally differentiated cells formed from the fusion of
monocyte/macrophage lineage cells. The data presented
here support the role of CCL2 in regulating monocyte lin-
eage cells in the development of prostate cancer and dem-
onstrates that inhibition of CCL2 changes the host–tumor
microenvironment by inhibiting the infiltration of immune cells
that promote tumor development.
The relationship between cancer and inflammation has
been recognized since the 1860s when Virchow observed
leukocytes in neoplastic tissues [12]. Proinflammatory cyto-
kines and chemokines, produced by cancer cells, normal
cells of the tumor microenvironment, and invading inflam-
matory cells, have been shown to facilitate tumor growth,
invasion, and metastasis by producing chemotactic factors,
inducing the production of angiogenic factors, and contribut-
ing to the maintenance of a chronic state of inflammation
through self-activating feedback loops [12–14]. These cyto-
kines and chemokines can contribute to the morbidity and
mortality of patients, resulting in the activation of multiple
signaling pathways that lead to clinical syndromes such as
cachexia and coagulopathy [15].
Figure 4. CCL2 stimulates Akt and p70S6 kinase activation in VCaP cells. CCL2 induces Akt phosphorylation (A) and p70S6 kinase phosphorylation (B) in
a dose-dependent fashion. (C) VCaP cells (8  105 cells/well) were treated with hrCCL2 (100 ng/ml) for 24 to 72 hours in the presence or in the absence
of CNTO888 (30 g/ml). The proliferation of VCaP cells was assessed by WST-1 assay (5 control; x 30 g/ml CNTO888; E 100 ng/ml hrCCL2; z 100 ng/ml
hrCCL2 + 30 g/ml CNTO888).
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Traditionally, cancer therapy has been directed at the
development of cytotoxic agents and, more recently, at the
development of ‘‘targeted’’ therapies that inhibit the dys-
regulation or overexpression of a particular oncogene or sig-
nal transduction pathway. However, cancer is the result of a
complex interplay between a growing tumor and local and
systemic host responses to the presence of malignancy. The
potential exists not only to treat cancer cells themselves but
also to decrease the morbidity and mortality of cancer by
targeting factors produced by the cancer and the host. CCL2
presents such a target. Therapeutics disrupting the effects of
CCL2 are being tested in multiple inflammatory diseases [6].
Targeting the direct and indirect effects of CCL2 has great
potential for development in the treatment of prostate cancer
and other malignancies.
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